Milestone Scientific to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference on December 11th, 2024
Milestone Scientific (NYSE: MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024 at the New York Athletic Club in New York City.
CEO Arjan Haverhals and Chairman Neal Goldman will represent the company, with Haverhals conducting one-on-one meetings with investors and analysts throughout the conference day. The conference provides emerging growth companies the opportunity to connect with institutional and individual investors in a unique format.
Milestone Scientific (NYSE: MLSS), sviluppatore di strumenti informatici per la somministrazione di farmaci per iniezioni indolori e precise, ha annunciato la sua partecipazione al 13° Annual Discovery One-on-One Investor Conference di The Benchmark Company. L'evento si terrà il 11 dicembre 2024 presso il New York Athletic Club a New York City.
Il CEO Arjan Haverhals e il presidente Neal Goldman rappresenteranno l'azienda, con Haverhals che condurrà incontri individuali con investitori e analisti durante l'intera giornata della conferenza. La conferenza offre alle aziende in crescita l'opportunità di connettersi con investitori istituzionali e individuali in un formato unico.
Milestone Scientific (NYSE: MLSS), un desarrollador de instrumentos informáticos para la administración de medicamentos mediante inyecciones indoloras y precisas, ha anunciado su participación en la 13ª Conferencia Anual Discovery One-on-One Investor de The Benchmark Company. El evento tendrá lugar el 11 de diciembre de 2024 en el New York Athletic Club en la ciudad de Nueva York.
El CEO Arjan Haverhals y el presidente Neal Goldman representarán a la empresa, y Haverhals realizará reuniones individuales con inversores y analistas durante todo el día de la conferencia. La conferencia brinda a las empresas emergentes la oportunidad de conectar con inversores institucionales e individuales en un formato único.
Milestone Scientific (NYSE: MLSS)는 무통 및 정밀 주사를 위한 컴퓨터화된 약물 전달 기기를 개발하는 회사로, The Benchmark Company의 제13회 연례 Discovery One-on-One Investor Conference에 참여한다고 발표했습니다. 이 행사는 2024년 12월 11일 뉴욕시의 뉴욕 체육관(New York Athletic Club)에서 열릴 예정입니다.
CEO Arjan Haverhals와 회장 Neal Goldman이 회사를 대표하며, Haverhals는 컨퍼런스 당일 동안 투자자 및 분석가와의 일대일 회의를 진행할 예정입니다. 이 컨퍼런스는 신생 성장 기업에게 독특한 형식으로 기관 및 개인 투자자와 연결할 기회를 제공합니다.
Milestone Scientific (NYSE: MLSS), un développeur d'instruments de livraison de médicaments informatisés pour des injections indolores et précises, a annoncé sa participation à la 13ème Conférence Annuelle Discovery One-on-One Investor de The Benchmark Company. L'événement se déroulera le 11 décembre 2024 au New York Athletic Club à New York.
Le PDG Arjan Haverhals et le président Neal Goldman représenteront l'entreprise, avec Haverhals qui mènera des réunions individuelles avec des investisseurs et des analystes tout au long de la journée de la conférence. La conférence offre aux entreprises en croissance émergentes l'occasion de se connecter avec des investisseurs institutionnels et individuels dans un format unique.
Milestone Scientific (NYSE: MLSS), ein Entwickler von computergestützten Arzneimittelabgabegeräten für schmerzarme und präzise Injektionen, hat seine Teilnahme an der 13. jährlichen Discovery One-on-One Investor Conference von The Benchmark Company angekündigt. Die Veranstaltung findet am 11. Dezember 2024 im New York Athletic Club in New York City statt.
CEO Arjan Haverhals und Vorsitzender Neal Goldman werden das Unternehmen vertreten, wobei Haverhals den ganzen Tag über Einzelgespräche mit Investoren und Analysten führen wird. Die Konferenz bietet aufstrebenden Wachstumsunternehmen die Möglichkeit, sich in einem einzigartigen Format mit institutionellen und privaten Investoren zu vernetzen.
- None.
- None.
ROSELAND, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its CEO Arjan Haverhals and Chairman Neal Goldman will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York City.
The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Arjan Haverhals, CEO of Milestone Scientific will be participating in one-on-one meetings with investors and analysts throughout the day.
To schedule a one-on-one meeting , you may submit your request online via the registration link provided. To register for the conference, please visit https://www.meetmax.com/sched/event_112571/investor_reg_new.html?attendee_role_id=INVESTOR
About The Benchmark Company
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities. https://www.benchmarkcompany.com.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
When is Milestone Scientific (MLSS) presenting at The Benchmark Company's Discovery Conference?
Who will represent Milestone Scientific (MLSS) at the Benchmark Discovery Conference 2024?
What type of meetings will Milestone Scientific (MLSS) conduct at the Benchmark Conference?
Where will the Benchmark Company's Discovery Conference featuring MLSS be held?
